Abstract |
On November 16, 2011, the U.S. Food and Drug Administration (FDA) granted full approval to ruxolitinib, ( Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis. This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2). The primary efficacy endpoint was the proportion of patients who experienced a reduction in spleen volume of ≥ 35% at 24 weeks (study 1) or 48 weeks (study 2). The key secondary endpoint in study 1 was the proportion of patients who experienced a ≥ 50% improvement from baseline in myelofibrosis total symptom score at 24 weeks. The results of these studies showed that a greater proportion of patients treated with ruxolitinib experienced a ≥ 35% reduction in spleen volume as compared with those treated with placebo (42% vs. 1%, P < 0.0001) or best available therapy (29% vs. 0%, P < 0.0001). A greater proportion of patients in study 1 experienced a ≥ 50% reduction in the myelofibrosis total symptom score during treatment with ruxolitinib than with placebo (46% vs. 5%, P < 0.0001). Ruxolitinib treatment was associated with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia. This is the first drug approved for myelofibrosis.
|
Authors | Albert Deisseroth, Edvardas Kaminskas, Joseph Grillo, Wei Chen, Haleh Saber, Hong L Lu, Mark D Rothmann, Satjit Brar, Jian Wang, Christine Garnett, Julie Bullock, Laurie B Burke, Atiqur Rahman, Rajeshwari Sridhara, Ann Farrell, Richard Pazdur |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 18
Issue 12
Pg. 3212-7
(Jun 15 2012)
ISSN: 1557-3265 [Electronic] United States |
PMID | 22544377
(Publication Type: Journal Article)
|
Copyright | ©2012 AACR. |
Chemical References |
- Nitriles
- Pyrazoles
- Pyrimidines
- ruxolitinib
- Janus Kinase 1
- Janus Kinase 2
|
Topics |
- Anemia
(chemically induced)
- Clinical Trials, Phase III as Topic
- Drug Approval
- Female
- Humans
- Janus Kinase 1
(antagonists & inhibitors)
- Janus Kinase 2
(antagonists & inhibitors)
- Male
- Neutropenia
(chemically induced)
- Nitriles
- Primary Myelofibrosis
(drug therapy)
- Pyrazoles
(adverse effects, pharmacology, therapeutic use)
- Pyrimidines
- Randomized Controlled Trials as Topic
- Thrombocytopenia
(chemically induced)
- United States
- United States Food and Drug Administration
|